

Financial Tear Sheet

Corporate Profile

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company's clinical development pipeline includes multiple hormone therapy products at various stages of clinical development. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: vitamedmdrx.com and bocagreenmd.com.

Stock Performance

TXMD (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$5.10
Change (%)	▲ 0.25 (5.15%)
Volume	4,369,462
52 Week Low	\$3.50
Market Cap	\$1,040,538,424
Rolling EPS	-0.45
PE Ratio	0
Shares Outstanding	204,027,142

Data as of 10/20/17 4:00 p.m. ET



Recent Headlines & Events

- 10/05/17 [TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017](#)
- 09/28/17 [TherapeuticsMD Announces Closing of Common Stock Offering](#)
- 09/25/17 [TherapeuticsMD Announces Pricing of Common Stock Offering](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
10/06/17	CERTNAS
10/06/17	8-A12B
10/06/17	25
10/04/17	8-K

Corporate Governance

EXECUTIVE TEAM

Robert G. Finizio	Chief Executive Officer, Co-Founder, and Director President
John Milligan	Chief Financial Officer
Dan Cartwright	Chief Commercial Officer
Dawn Halkuff	

CLINICAL TEAM

Brian Bernick, M.D., F.A.C.O.G.	Co-Founder and Chief Clinical Officer
Sebastian Mirkin, M.D.	Chief Medical Officer
Julia Amadio	Chief Product Officer
Marian Walker, J.D.	General Counsel
Christine Miller, Pharm.D.	Chief Regulatory and Quality Officer

OPERATIONS TEAM

Mitchell Krassan	Chief Strategy Performance Officer
Jason Spitz	Vice President of Marketing
Christian Bloomgren	Vice President of Sales
Michael Donegan	Vice President of Finance

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	185	1,076.37	94.5	204,564,310
Mutual Fund	216	620.47	50.2	108,714,656
Insider *	3	112.35	8.7	18,914,114

*Insider values reflect direct beneficial ownership.
Data Provided by Thomson Reuters

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Fidelity Management & Research Company	25,601,770	11.8	-3,054,461	06/30/17
Finizio (Robert G)	20,643,559	9.5	-145,000	04/17/17
T. Rowe Price Associates, Inc.	20,025,126	9.3	-5,547,160	06/30/17
The Boston Company Asset Management, LLC	19,532,426	9.0	1,689,632	06/30/17
BlackRock Institutional Trust Company, N.A.	10,518,405	4.9	287,897	06/30/17
Franklin Advisers, Inc.	10,260,962	4.7	-75,356	06/30/17
The Vanguard Group, Inc.	10,231,081	4.7	429,211	06/30/17
Smith (Robert J)	10,056,770	4.7	2,199,265	04/17/17
JP Morgan Asset Management	7,905,984	3.7	1,161,114	06/30/17
Bernick (Brian A)	6,827,371	3.2	-101,128	04/17/17

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)